Inhibitory effect of the noncamptothecin topoisomerase i inhibitor LMP-400 on female mice models and human pheochromocytoma cells

Jan Schovanek, Petra Bullova, Yasin Tayem, Alessio Giubellino, Robert Wesley, Nikoletta Lendvai, Svenja Nölting, Juraj Kopacek, Zdenek Frysak, Yves Pommier, Shivaani Kummar, Karel Pacak

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Metastatic pheochromocytoma continues to be an incurable disease, and treatment with conventional cytotoxic chemotherapy offers limited efficacy. In the present study, we evaluated a novel topoisomerase I inhibitor, LMP-400, as a potential treatment for this devastating disease. We found a high expression of topoisomerase I in human metastatic pheochromocytoma, providing a basis for the evaluation of a topoisomerase 1 inhibitor as a therapeutic strategy. LMP-400 inhibited the cell growth of established mouse pheochromocytoma cell lines and primary human tumor tissue cultures. In a study performed in athymic female mice, LMP-400 demonstrated a significant inhibitory effect on tumor growth with two drug administration regimens. Furthermore, low doses of LMP-400 decreased the protein levels of hypoxiainducible factor 1 (HIF-1α), one of a family of factors studied as potential metastatic drivers in these tumors. The HIF-1α decrease resulted in changes in the mRNA levels of HIF-1 transcriptional targets. In vitro, LMP-400 showed an increase in the growth-inhibitory effects in combination with other chemotherapeutic drugs that are currently used for the treatment of pheochromocytoma. We conclude that LMP-400 has promising antitumor activity in preclinical models of metastatic pheochromocytoma and its use should be considered in future clinical trials.

Original languageEnglish (US)
Pages (from-to)4094-4104
Number of pages11
JournalEndocrinology
Volume156
Issue number11
DOIs
StatePublished - Nov 2015

Fingerprint Dive into the research topics of 'Inhibitory effect of the noncamptothecin topoisomerase i inhibitor LMP-400 on female mice models and human pheochromocytoma cells'. Together they form a unique fingerprint.

  • Cite this

    Schovanek, J., Bullova, P., Tayem, Y., Giubellino, A., Wesley, R., Lendvai, N., Nölting, S., Kopacek, J., Frysak, Z., Pommier, Y., Kummar, S., & Pacak, K. (2015). Inhibitory effect of the noncamptothecin topoisomerase i inhibitor LMP-400 on female mice models and human pheochromocytoma cells. Endocrinology, 156(11), 4094-4104. https://doi.org/10.1210/en.2015-1476